After 3-City Tour, PM Modi To Interact With Gennova Biopharma, Biological E & Dr Reddy Teams Involved In Developing Covid Vaccine

The Central Drug Standard Control Organisation has granted permission for the pre-clinical test, examination, and analysis of COVID-19 Vaccine to seven firms including the Serum Institute of India and the Gennova Biopharmaceuticals.

PM Narendra Modi (@narendramodi/Twitter)

Two days after visiting three cities to personally review the Coronavirus vaccine development and manufacturing process, Prime Minister Narendra Modi is set to interact with three teams on Monday which are involved in developing Covid-19 shots in India. The teams he will interact with are from Gennova Biopharma, Biological E and Dr. Reddy's. The Prime Minister's Office took to the Twitter handle to inform that "Tomorrow, on 30th November 2020, PM Narendra Modi will interact, via video conferencing, with three teams that are involved in developing a COVID-19 vaccine. The teams he will interact with are from Gennova Biopharma, Biological E and Dr. Reddy's."

Modi's Monday interaction with the three Pharma teams will come two days after he visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune on Saturday to personally review the vaccine development and manufacturing process.

India Coronavirus Vaccine Development Updates

According to a PTI report, the Central Drug Standard Control Organisation has granted permission for the pre-clinical test, examination, and analysis of COVID-19 Vaccine to seven firms including the Serum Institute of India (SII) and the Gennova Biopharmaceuticals. As per the latest development, the Pune Based Serum Institute will apply within two weeks for an emergency use license of the coronavirus vaccine being developed by the University of Oxford and pharma giant AstraZeneca. Speaking of the Dr. Reddy’s Laboratories, the Drug Controller General of India (DCGI) last month gave nod to Dr. Reddy’s Lab to conduct mid to late stage clinical human trials of the Russian vaccine candidate Sputnik V. Sputnik V is the Covid-19 vaccine. In September 2020, Dr. Reddy’s Lab and RDIF entered into partnership to conduct clinical trials and distribute the vaccine in the country. As part of the agreement the RDIF will supply 100 million doses of the Vaccine to the country upon approval.